Laura A. VanBlargan - Concepedia

Author

Laura A. VanBlargan

Washington University in St. Louis ORCID

Also Known As

Davis, Keanu, Laura A VanBlargan, Laura A. VanBlargan, Laura VanBlargan, VanBlargan, Laura Anne

Publications

7.7K

Citations

H-Index

Concepts

All Affiliations

Washington University in St. Louis Vanderbilt University Medical Center The University of Texas Medical Branch at Galveston National Institutes of Health Vir Biotechnology (Switzerland)

About

Laura A. VanBlargan is an author at Washington University in St. Louis specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	23	5.2K
2	Immunology	20	23	5.2K
3	Cell Biology	4	4	561
4	Biomolecular Engineering	1	1	115
5	Microbiology	1	1	14

Laura A. VanBlargan

Publications

7.4K

Citations

H-Index

Page 1

	Year	Citations
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, Nature VaccinationNeutralizing AntibodiesVaccine TargetHumoral ResponseImmunology	2021	1.2K
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies Rita E. Chen, Xianwen Zhang, James Brett Case, Nature Medicine	2021	1K
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization Zhuoming Liu, Laura A. VanBlargan, Louis-Marie Bloyet, Cell Host & Microbe Sars-cov-2 Spike MutationsViral PathogenesisImmunologyVirologySerum Antibody Neutralization	2021	841
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies Laura A. VanBlargan, John M. Errico, Peter Halfmann, Nature Medicine VaccinationTherapeutic Monoclonal AntibodiesImmunologyViral PathogenesisAntiviral Response	2022	758
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2 Ahmed O. Hassan, Natasha M. Kafai, Igor P. Dmitriev, Cell VaccinationVaccine SafetyVaccine DevelopmentLower Respiratory TractsImmunology	2020	614
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein Naveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, Cell Vaccine TargetN-terminal DomainViral PathogenesisImmunologySars-cov-2 Spike Protein	2021	403
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains Rita E. Chen, Emma S. Winkler, James Brett Case, Nature Sars-cov-2 Variant StrainsVaccine TargetImmunologyMedicineCovid-19	2021	260
Dengue viruses cluster antigenically but not as discrete serotypes Leah C. Katzelnick, Judith M. Fonville, Gregory D. Gromowski, Science	2015	238
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, Nature VaccinationNeutralizing AntibodiesVaccine TargetHumoral ResponseImmunology	2021	213
Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell Maritza Puray‐Chavez, Kyle M. LaPak, Travis P. Schrank, Cell Reports Viral DiagnosticsSars-cov-2 InfectionRespiratory DiseasesDisease SeveritySystematic Analysis	2021	149

Page 1